These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 20714241)
21. Prolyl hydroxylases as regulators of cell metabolism. Boulahbel H; Durán RV; Gottlieb E Biochem Soc Trans; 2009 Feb; 37(Pt 1):291-4. PubMed ID: 19143649 [TBL] [Abstract][Full Text] [Related]
22. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. Kido M; Du L; Sullivan CC; Li X; Deutsch R; Jamieson SW; Thistlethwaite PA J Am Coll Cardiol; 2005 Dec; 46(11):2116-24. PubMed ID: 16325051 [TBL] [Abstract][Full Text] [Related]
23. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104 [TBL] [Abstract][Full Text] [Related]
24. Prolyl hydroxylase and hypoxia inducible factor: potential targets for cancer therapy. Prabhu V; Guruvayoorappan C Immunopharmacol Immunotoxicol; 2011 Sep; 33(3):568-75. PubMed ID: 21226555 [TBL] [Abstract][Full Text] [Related]
29. Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Erez N; Milyavsky M; Eilam R; Shats I; Goldfinger N; Rotter V Cancer Res; 2003 Dec; 63(24):8777-83. PubMed ID: 14695194 [TBL] [Abstract][Full Text] [Related]
30. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Jeon H; Kim H; Choi D; Kim D; Park SY; Kim YJ; Kim YM; Jung Y Mol Pharmacol; 2007 Jun; 71(6):1676-84. PubMed ID: 17377063 [TBL] [Abstract][Full Text] [Related]
36. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia. Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122 [TBL] [Abstract][Full Text] [Related]
37. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease. Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388 [TBL] [Abstract][Full Text] [Related]
38. The role of HIF prolyl hydroxylases in tumour growth. Jokilehto T; Jaakkola PM J Cell Mol Med; 2010 Apr; 14(4):758-70. PubMed ID: 20178464 [TBL] [Abstract][Full Text] [Related]
39. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Bernhardt WM; Gottmann U; Doyon F; Buchholz B; Campean V; Schödel J; Reisenbuechler A; Klaus S; Arend M; Flippin L; Willam C; Wiesener MS; Yard B; Warnecke C; Eckardt KU Proc Natl Acad Sci U S A; 2009 Dec; 106(50):21276-81. PubMed ID: 19934037 [TBL] [Abstract][Full Text] [Related]
40. Stabilization of Hypoxia-inducible Factor by DMOG Inhibits Development of Chronic Hypoxia-Induced Right Ventricular Remodeling. Zhang S; Ma K; Liu Y; Pan X; Chen Q; Qi L; Li S J Cardiovasc Pharmacol; 2016 Jan; 67(1):68-75. PubMed ID: 26485211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]